Key Factors Influencing Later-Line Treatment Selection for Patients With Metastatic Colorectal Cancer

Decera Clinical Education Oncology Podcast · Dec 17, 2021 · 12m

In this episode, Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, PhD, discuss the clinical data that inform how they select regorafenib and TAS-102 as later-line treatment for patients with mCRC, with topics including:

Transitioning from second- to third-line therapy

Factors in selecting among available therapies

Key predictors of improved outcomes with regorafenib vs TAS-102

Presenters:

Chiara Cremolini, MD, PhD

Medical Oncologist

Unit of Medical Oncology 2

Azienda Ospedaliero-Universitaria Pisana

Professor

Department of Translational Research and New Technologies in Medicine and…